Sovran Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Sovran Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-500	Closed	-$214K	–	573
2025 Q3	$214K	Buy	+500	New	+$187K	0.02%	500

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sovran Advisors's MDGL Position: Q4 2025 in Review

Sovran Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 500 shares — an estimated $214K sold.

Sovran Advisors first reported a position in MDGL in Q3 2025 and held it in 1 quarter. The position peaked at $214K in Q3 2025. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

Sovran Advisors reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Sovran Advisors sold 500 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $214K.
Sovran Advisors first reported a position in Madrigal Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Sovran Advisors's Madrigal Pharmaceuticals position peaked at $214K in Q3 2025.
387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on Sovran Advisors's 13F filing for Q4 2025, filed 20 Jan 2026.